ISB 2301
/ Glenmark, Ichnos Glenmark Innovation
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 20, 2026
Glenmark Pharmaceuticals Ichnos Glenmark Innovation Unveils New Multispecific Candidate ISB 2301
(InvestyWise)
- "IGI plans to file an Investigational New Drug (IND) application by the end of 2026 and anticipates initiating clinical trials in 2027, leveraging its proprietary BEAT platform."
IND • New molecule • New trial • Solid Tumor
1 to 1
Of
1
Go to page
1